Nephrogenic Fibrosing Dermopathy in a Patient with Systemic Lupus Erythematosus and Acute Lupus Nephritis

Sanchez-Ross, Monica; Snyder, Renée; Colome‐Grimmer, Maria; Blumberg, Mark; Huttenbach, Yve; Raimer, S.

doi:10.1111/j.1525-1470.2007.00437.x

Cited by 12 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some patients have also described muscle weakness and inflexibility of their joints. [3][4][5] During these early stages the cutaneous findings of NSF are non-specific and commonly mistaken for cellulitis, 3 consisting of erythema, oedema and a palpable warmth. This oedema commonly involves the lower extremities in a distal to proximal distribution resembling fluid overload.…”

Section: Manifestationsmentioning

confidence: 98%

See 1 more Smart Citation

MRI safety; nephrogenic systemic fibrosis and other risks

Gauden

Phal

Drummond

2010

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Section: Manifestationsmentioning

confidence: 98%

“…3 It has also been noted in paediatric, as well as elderly patients, although it seems to most frequently occur in the middle aged. 3,5,[33][34][35] The condition has also been identified in a wide variety of ethnicities which points against a genetic link or predisposition with this disease. 3 …”

Section: Risk Factorsmentioning

confidence: 98%

MRI safety; nephrogenic systemic fibrosis and other risks

Gauden

Phal

Drummond

2010

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…The earliest symptoms described by patients are swelling, redness, pruritus and pain in the limbs (23–25). Some patients describe muscle weakness.…”

Section: Early Clinical Findingsmentioning

confidence: 99%

NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment

Knopp¹,

Cowper

2008

Seminars in Dialysis

View full text Add to dashboard Cite

Nephrogenic systemic fibrosis (NSF) is a progressive, debilitating, and emotionally distressing disease that can affect patients with renal dysfunction. Prevention, early recognition and early treatment are essential to limiting its impact. The most significant risk factors for developing NSF are chronic or significant acute kidney disease (usually necessitating dialysis) and the administration of gadolinium-containing contrast agents (GCCA). Early symptoms include swelling, redness, pruritus, and pain in the limbs, sometimes with muscle weakness. Early signs are edema, erythema, and occasionally palpable warmth of the involved extremities; there may be florid scleral telangiectasia resembling conjunctivitis. We must redouble our efforts to avoid the administration of GCCA to patients with renal insufficiency. The most effective treatment for NSF to date is maximization of renal function via medical therapy or transplantation. There are data to support a beneficial effect from extracorporeal photopheresis, and all patients can gain from physical therapy.

show abstract

Nephrogenic systemic fibrosis in liver disease: A systematic review

Mazhar

Shiehmorteza

Kohl

et al. 2009

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Nephrogenic systemic fibrosis (NSF) may develop in patients with liver disease, a fact highlighted by Food and Drug Administration (FDA) announcements cautioning against the use of gadolinium‐based contrast agents (GBCAs) in select liver disease patients. The purpose of this systematic literature review is to characterize the risk of NSF in patients with liver disease. All published articles on NSF from September 2000 through August 2008, were identified via PubMed searches and examination of articles' reference lists. Two reviewers independently read each article and identified unique patients with biopsy‐proven or suspected NSF. Data on demographics, liver status, renal status, and GBCA exposure were collected. A total of 324 articles were reviewed, with 108 articles containing case descriptions of 335 unique NSF patients. After excluding the 95/335 (28%) patients in whom the presence or absence of liver disease was uncertain, liver disease was confirmed present in 41/239 (17%) patients. Renal insufficiency could be assessed in 35 of the liver disease patients; severe renal insufficiency, defined as a glomerular filtration rate (GFR) or estimated GFR (eGFR) <30 mL/min/1.73 m2 or dialysis requirement, was present in 34/35 (97%) patients. The lone patient who developed NSF with mild/moderate renal insufficiency was atypical and received a total gadodiamide load of 0.76 mmol/kg over a 10‐week period periliver transplantation. The published medical literature demonstrates that patients with liver disease who develop NSF also have severe renal insufficiency, suggesting that liver disease does not confer a risk for NSF beyond that of the underlying renal insufficiency. J. Magn. Reson. Imaging 2009;30:1313–1322. © 2009 Wiley‐Liss, Inc.

show abstract

Nephrogenic Fibrosing Dermopathy in a Patient with Systemic Lupus Erythematosus and Acute Lupus Nephritis

Cited by 12 publications

References 20 publications

MRI safety; nephrogenic systemic fibrosis and other risks

MRI safety; nephrogenic systemic fibrosis and other risks

NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment

Nephrogenic systemic fibrosis in liver disease: A systematic review

Contact Info

Product

Resources

About